With 35 years of experience in the pharmaceutical industry, Jim is one of a small group of executives responsible for building Gilead Sciences from a pre-commercial start-up to a top-20 biopharmaceutical company over the course of two decades. During his 22-year tenure, Jim oversaw or led the launch of 24 products, 11 of which achieved blockbuster status, including some of the most important innovations of the last several decades (Sovaldi & Harvoni in HepC, Biktarvy in HIV, Truvada in PrEP). He served as Gilead's EVP of Worldwide Commercial Operations & Chief Commercial Officer, while also representing Gilead with policymakers in DC and on the executive committee of BIO. In his role as Senior Advisor to BCG, Jim works closely with the majority of the top-20 pharmaceutical companies, as well as biotech, private equity, major PBM's and payers, key provider networks and academic research centers. He is a recognized expert in the intersection of policy, pricing, and access, and a frequent speaker/panellist on the topic. Jim serves on the Board of Directors of Vera Therapeutics, Sangamo Therapeutics, CytomX Therapeutics, and Pulmocide. He is also the Chairman of the Board of IntegriChain, a Nordic Capital company. From 2020 to 2024, he served as the CEO of IntraBio. In addition to his advisory work for BCG, Jim serves as a Senior Advisor to Blackstone, Longitude Capital, Exelixis, and Cytokinetics. He holds a BA in Economics from Boston College.